scPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Update

scPharmaceuticals, Inc. (NASDAQ:SCPH) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totaling 1,340,000 shares, a growth of 32.7% from the July 31st total of 1,010,000 shares. Based on an average trading volume of 682,600 shares, the days-to-cover ratio is presently 2.0 days. Based on an average trading volume of 682,600 shares, the days-to-cover ratio is presently 2.0 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Craig Hallum cut scPharmaceuticals from a “buy” rating to a “hold” rating and set a $6.00 target price for the company. in a report on Monday, August 25th. HC Wainwright cut scPharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $5.35 price target for the company. in a report on Friday, August 29th. Wall Street Zen raised scPharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Maxim Group cut scPharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 25th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in scPharmaceuticals by 5.8% in the second quarter. Rhumbline Advisers now owns 54,500 shares of the company’s stock valued at $208,000 after purchasing an additional 3,001 shares during the period. Lido Advisors LLC increased its position in scPharmaceuticals by 14.6% in the 2nd quarter. Lido Advisors LLC now owns 27,500 shares of the company’s stock valued at $105,000 after acquiring an additional 3,500 shares during the period. Captrust Financial Advisors increased its position in scPharmaceuticals by 9.0% in the 2nd quarter. Captrust Financial Advisors now owns 43,746 shares of the company’s stock valued at $167,000 after acquiring an additional 3,621 shares during the period. Police & Firemen s Retirement System of New Jersey increased its position in scPharmaceuticals by 63.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,336 shares of the company’s stock valued at $36,000 after acquiring an additional 3,628 shares during the period. Finally, Bank of America Corp DE boosted its holdings in scPharmaceuticals by 9.0% in the 4th quarter. Bank of America Corp DE now owns 44,037 shares of the company’s stock valued at $156,000 after purchasing an additional 3,647 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Trading Down 0.2%

Shares of scPharmaceuticals stock opened at $5.61 on Thursday. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $6.28. The stock has a 50 day moving average of $5.01 and a 200 day moving average of $3.76. The firm has a market capitalization of $299.01 million, a price-to-earnings ratio of -3.10 and a beta of 0.35. The company has a debt-to-equity ratio of 3.86, a quick ratio of 3.14 and a current ratio of 3.85.

scPharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%.The firm had revenue of $16.04 million for the quarter, compared to analysts’ expectations of $15.41 million. As a group, research analysts predict that scPharmaceuticals will post -1.53 earnings per share for the current year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.